ChemoCentryx (CCXI) CCX559 Featured in Poster Presentation at AACR

ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company’s orally-administered small molecule PD-L1 inhibitor, CCX559, will be featured in a poster presentation at the virtual 2021 Annual Meeting of the American Association for Cancer Research (AACR). The poster presentation, which showcases CCX559’s ability to induce anti-tumor immunity, will go live on Saturday, April 10 at 8:30 a.m. ET as part of the Novel Antitumor Agents Session (PO.ET06.03).

PD-L1/PD-1 interaction is one of the major checkpoints that limit effector T cell function against cancer cells. As a next generation therapy, small molecule inhibitors of PD-L1 may have advantageous properties compared to approved monoclonal antibodies, such as better penetration into solid tumors, reduced immunogenicity, lack of Fc-mediated side effects, convenience of oral administration, and lower cost of goods.

The study featured in the AACR poster presentation demonstrated that CCX559 potentially employs distinct mechanisms to inhibit PD-L1 compared to the anti-human PD-L1 antibodies. In murine tumor models, orally administered CCX559 reduced tumor growth similarly to a clinically-approved anti-human PD-L1 antibody.

Based on CCX559’s unique mechanism of PD-L1 inhibition, strong anti-tumor activity, desirable drug properties, and good safety profile, the Company plans to advance CCX559 into clinical development in the first half of 2021.

You May Also Be Interested In

• AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab
• Abeona Therapeutics (ABEO) Receives FDA Complete Response Letter on Pz-cel
• Petros Pharmaceuticals (PTPI) Expands Online Distribution for Prescription STENDRA